

Nadine Al-Naamani, M.D., M.S.  
Perelman School of Medicine at the University of Pennsylvania  
Philadelphia, Pennsylvania

Beth L. Roman, Ph.D.  
University of Pittsburgh Graduate School of Public Health  
Pittsburgh, Pennsylvania

Paul B. Yu, M.D., Ph.D.  
Brigham and Women's Hospital  
Boston, Massachusetts  
and  
Harvard Medical School  
Boston, Massachusetts

Michael B. Fallon, M.D.  
University of Arizona  
Phoenix, Arizona

Mark T. Gladwin, M.D.\*  
University of Pittsburgh  
Pittsburgh, Pennsylvania

Steven M. Kawut, M.D., M.S.†  
Perelman School of Medicine at the University of Pennsylvania  
Philadelphia, Pennsylvania

For the PVCLD2 Study Group

ORCID ID: 0000-0001-7896-0608 (S.M.K.).

\*M.T.G. is Associate Editor of *AJRCCM*. His participation complies with American Thoracic Society requirements for recusal from review and decisions for authored works.

†Corresponding author (e-mail: kawut@upenn.edu).

## References

- Fallon MB, Krowka MJ, Brown RS, Trotter JF, Zacks S, Roberts KE, *et al.*; Pulmonary Vascular Complications of Liver Disease Study Group. Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates. *Gastroenterology* 2008;135:1168–1175.
- Colle IO, Moreau R, Godinho E, Belghiti J, Ettori F, Cohen-Solal A, *et al.* Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. *Hepatology* 2003;37:401–409.
- Tillet E, Ouarné M, Desroches-Castan A, Mallet C, Subileau M, Didier R, *et al.* A heterodimer formed by bone morphogenetic protein 9 (BMP9) and BMP10 provides most BMP biological activity in plasma. *J Biol Chem* 2018;293:10963–10974.
- Bidart M, Ricard N, Levet S, Samson M, Mallet C, David L, *et al.* BMP9 is produced by hepatocytes and circulates mainly in an active mature form complexed to its prodomain. *Cell Mol Life Sci* 2012;69:313–324.
- David L, Mallet C, Keramidas M, Lamandé N, Gasc JM, Dupuis-Girod S, *et al.* Bone morphogenetic protein-9 is a circulating vascular quiescence factor. *Circ Res* 2008;102:914–922.
- Hoffman JI. Normal and abnormal pulmonary arteriovenous shunting: occurrence and mechanisms. *Cardiol Young* 2013;23:629–641.
- Hodgson J, Swietlik EM, Salmon RM, Hadinnapola C, Nikolic I, Wharton J, *et al.* Characterization of *GDF2* mutations and levels of BMP9 and BMP10 in pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2020;201:575–585.
- Long L, Ormiston ML, Yang X, Southwood M, Gräf S, Machado RD, *et al.* Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension. *Nat Med* 2015;21:777–785.
- Nikolic I, Yung LM, Yang P, Malhotra R, Paskin-Flerlage SD, Dinter T, *et al.* Bone morphogenetic protein 9 is a mechanistic biomarker of portopulmonary hypertension. *Am J Respir Crit Care Med* 2019;199:891–902.
- DuBrock HM, Krowka MJ, Forde KA, Krok K, Patel M, Sharkoski T, *et al.* Clinical impact of intrapulmonary vascular dilatation in candidates for liver transplant. *Chest* 2018;153:414–426.
- Forde KA, Fallon MB, Krowka MJ, Sprys M, Goldberg DS, Krok KL, *et al.*; Pulmonary Vascular Complications of Liver Disease 2 Study Group. Pulse oximetry is insensitive for detection of hepatopulmonary syndrome in patients evaluated for liver transplantation. *Hepatology* 2019;69:270–281.
- Kavarana MN, Jones JA, Stroud RE, Bradley SM, Ikonomidis JS, Mukherjee R. Pulmonary arteriovenous malformations after the superior cavopulmonary shunt: mechanisms and clinical implications. *Expert Rev Cardiovasc Ther* 2014;12:703–713.

Copyright © 2020 by the American Thoracic Society



## High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis



To the Editor:

We read with interest the article by Dooley and colleagues, which showed that high-dose isoniazid (10–15 mg/kg) had early bactericidal activity for *Mycobacterium tuberculosis* (MTB) strains with *inhA* mutations similar to that observed with normal-dose isoniazid (5 mg/kg) for susceptible strains (1). The authors concluded that high-dose isoniazid represents a useful addition to second-line tuberculosis (TB) treatment regimens for patients with rifampicin-resistant TB and isolated *inhA* mutations.

We believe that high-dose isoniazid may also play an important role in first-line TB treatment. At present, the World Health Organization recommends adding a second-line TB drug (levofloxacin) to three first-line drugs (rifampicin, ethambutol, and pyrazinamide) in patients with TB resistant to isoniazid without concurrent rifampicin resistance. Isoniazid would not be included in this levofloxacin-strengthened first-line regimen (2). This recommendation has several major implications.

To implement this recommendation, rifampicin and isoniazid susceptibility testing should be performed, particularly in previously treated patients, who are at risk of initial resistance. Before prescribing levofloxacin for patients with rifampicin-susceptible/isoniazid-resistant TB, additional fluoroquinolone susceptibility testing is recommended (2). Access to rifampicin susceptibility testing has increased substantially, but access to isoniazid and fluoroquinolone susceptibility testing is still poor in most high-TB-burden countries, where samples still have to be transported to referral laboratories. Although novel diagnostic tools, such as Xpert MTB/XDR, are on the horizon, their widespread implementation will still take years. This will cause treatment delays of several months and result in losses to follow-up between the time of TB diagnosis and treatment initiation. In addition, not all rifampicin resistance is detected by frequently used rapid tests, such as Xpert MTB/RIF and

†This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (<http://creativecommons.org/licenses/by-nc-nd/4.0/>). For commercial usage and reprints, please contact Diane Gern (dgern@thoracic.org).

Author Contributions: T.D. wrote the first draft. B.C.d.J., A.P., M.B.S., L.L., and A.V.D. critically reviewed the subsequent versions. All authors approved the final version.

Originally Published in Press as DOI: 10.1164/rccm.202001-0201LE on March 4, 2020

GenoType MTBDR<sub>plus</sub>. *rpoB* mutations outside the 81-bp rifampicin resistance determining region are not covered by these commercial assays. Another, not unusual cause of missed rifampicin resistance is heteroresistance resulting from a mixed population of both susceptible and resistant TB bacilli (3). If patients with resistance to isoniazid and missed rifampicin resistance were treated with the World Health Organization levofloxacin-strengthened first-line regimen, resistance to fluoroquinolone would emerge rapidly. Because the efficacy of second-line TB treatment relies on a fluoroquinolone as a core drug, treatment options would be dramatically reduced. Finally, as shown by Dooley and colleagues, as well as by previous studies (4), high-dose isoniazid may overcome mutations that confer resistance to isoniazid and render normal doses ineffective (4). Excluding isoniazid, which has the highest early bactericidal activity of all first-line drugs, increases the risk of acquiring rifampicin resistance, as mutant bacilli may survive the early phase of TB treatment.

Moreover, Boeree and colleagues showed that high-dose rifampicin (35 mg/kg) was safe and reduced time to culture conversion when compared with normal-dose rifampicin (10 mg/kg) (5). Although isoniazid is used for its bactericidal activity against actively replicating bacilli, rifampicin has both a bactericidal effect against rapidly replicating bacilli and a sterilizing effect against dormant bacilli. Both types of action are needed to ensure a relapse-free cure (6).

Globally, about 11.6% of patients with recurrent TB have rifampicin-susceptible/isoniazid-resistant TB. Studies should compare high-dose first-line regimens with normal-dose regimens in terms of safety, treatment success, and acquired rifampicin resistance in patients with rifampicin-susceptible/isoniazid-resistant TB. If it is shown to be safe and efficacious, high-dose first-line treatment could be used in all patients with recurrent rifampicin-susceptible TB, regardless of initial isoniazid resistance, thus avoiding delays in retreatment. Such an improved use of first-line anti-TB drugs would have major advantages. No additional susceptibility testing beyond rifampicin testing would be required and there would be no delay between a diagnosis of rifampicin-susceptible recurrent TB and initiation of treatment. If first-line treatment could rely on first-line drugs only, second-line treatment options would be maximally safeguarded. ■

**Author disclosures** are available with the text of this letter at [www.atsjournals.org](http://www.atsjournals.org).

Tom Decroo, Ph.D.\*  
Institute of Tropical Medicine  
Antwerp, Belgium  
and  
Research Foundation Flanders  
Brussels, Belgium

Bouke C. de Jong, Ph.D.  
Institute of Tropical Medicine  
Antwerp, Belgium

Alberto Piubello, M.D.  
Damien Foundation  
Niamey, Niger  
and  
International Union Against Tuberculosis and Lung Disease  
Paris, France

Mahamadou Bassirou Souleymane, M.D.  
Damien Foundation  
Niamey, Niger

Lutgarde Lynen, Ph.D.  
Institute of Tropical Medicine  
Antwerp, Belgium

Armand Van Deun, Ph.D.  
Independent Consultant  
Leuven, Belgium

ORCID IDs: 0000-0002-1205-1484 (T.D.); 0000-0001-7183-4895 (L.L.).

\*Corresponding author (e-mail: [tdecroo@itg.be](mailto:tdecroo@itg.be)).

## References

1. Dooley KE, Miyahara S, von Groote-Bidlingmaier F, Sun X, Hafner R, Rosenkranz SL, *et al.*; A5312 Study Team. Early bactericidal activity of different isoniazid doses for drug resistant TB (INHinsight): a randomized open-label clinical trial. *Am J Respir Crit Care Med* [online ahead of print] 16 Jan 2020; DOI: 10.1164/rccm.201910-1960OC.
2. World Health Organization. WHO treatment guidelines for isoniazid-resistant tuberculosis: supplement to the WHO treatment guidelines for drug-resistant tuberculosis WHO/CDS/TB/2018; 2018 [accessed 2020 Jan 29]. Available from: [https://www.who.int/tb/publications/2018/WHO\\_guidelines\\_isoniazid\\_resistant\\_TB/en/](https://www.who.int/tb/publications/2018/WHO_guidelines_isoniazid_resistant_TB/en/).
3. Van Deun A, Aung KJM, Bola V, Lebeke R, Hossain MA, de Rijk WB, *et al.* Rifampin drug resistance tests for tuberculosis: challenging the gold standard. *J Clin Microbiol* 2013;51:2633–2640.
4. Katiyar SK, Bihari S, Prakash S, Mamtani M, Kulkarni H. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis [letter]. *Int J Tuberc Lung Dis* 2008;12:139–145.
5. Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, *et al.*; PanACEA consortium. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. *Lancet Infect Dis* 2017;17:39–49.
6. Van Deun A, Decroo T, Piubello A, de Jong BC, Lynen L, Rieder HL. Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs. *Int J Tuberc Lung Dis* 2018;22:239–245.

Copyright © 2020 by the American Thoracic Society



Reply to Decroo *et al.*



From the Authors:

We read with interest the letter from Decroo and colleagues referencing our INHinsight clinical trial, in which we show that 7 days of high-dose isoniazid (HD-INH) is active against pulmonary tuberculosis, with INH resistance mediated by *inhA* mutations (1).

Ⓓ This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (<http://creativecommons.org/licenses/by-nc-nd/4.0/>). For commercial usage and reprints, please contact Diane Gern ([dgern@thoracic.org](mailto:dgern@thoracic.org)).

Supported by the Division of AIDS, National Institute of Allergy and Infectious Diseases, NIH.

Author Contributions: K.E.D. wrote the first draft of the letter. S.M., F.v.G.-B., X.S., R.H., S.L.R., E.H.J., E.L.N., L.M., K.D., S.S., N.V., and A.H.D. critically reviewed and edited the letter. All authors approved the final version.

Originally Published in Press as DOI: 10.1164/rccm.202002-0359LE on March 4, 2020